Fulcrum Therapeutics (FULC) Total Liabilities: 2019-2025
Historic Total Liabilities for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $16.5 million.
- Fulcrum Therapeutics' Total Liabilities fell 24.06% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 24.06%. This contributed to the annual value of $17.7 million for FY2024, which is 21.41% down from last year.
- Fulcrum Therapeutics' Total Liabilities amounted to $16.5 million in Q3 2025, which was up 14.05% from $14.5 million recorded in Q2 2025.
- Fulcrum Therapeutics' Total Liabilities' 5-year high stood at $34.5 million during Q2 2022, with a 5-year trough of $14.2 million in Q1 2025.
- In the last 3 years, Fulcrum Therapeutics' Total Liabilities had a median value of $20.5 million in 2024 and averaged $20.0 million.
- Per our database at Business Quant, Fulcrum Therapeutics' Total Liabilities tumbled by 33.02% in 2021 and then grew by 27.75% in 2022.
- Fulcrum Therapeutics' Total Liabilities (Quarterly) stood at $23.5 million in 2021, then increased by 18.25% to $27.7 million in 2022, then fell by 18.89% to $22.5 million in 2023, then decreased by 21.41% to $17.7 million in 2024, then fell by 24.06% to $16.5 million in 2025.
- Its Total Liabilities stands at $16.5 million for Q3 2025, versus $14.5 million for Q2 2025 and $14.2 million for Q1 2025.